Dirk Behringer

6.8k total citations
69 papers, 2.2k citations indexed

About

Dirk Behringer is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dirk Behringer has authored 69 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 26 papers in Hematology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dirk Behringer's work include Hematopoietic Stem Cell Transplantation (15 papers), Immunotherapy and Immune Responses (9 papers) and Multiple Myeloma Research and Treatments (8 papers). Dirk Behringer is often cited by papers focused on Hematopoietic Stem Cell Transplantation (15 papers), Immunotherapy and Immune Responses (9 papers) and Multiple Myeloma Research and Treatments (8 papers). Dirk Behringer collaborates with scholars based in Germany, United States and Switzerland. Dirk Behringer's co-authors include K. Mross, Jürgen Finke, Stephan Mielke, Roland Mertelsmann, Alex Sparreboom, Seth M. Steinberg, A. Lindemann, Hartmut Bertz, Regina Kunzmann and Claudia Schmoor and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Dirk Behringer

67 papers receiving 2.1k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Dirk Behringer	1.1k	633	630	424	388	69	2.2k
Yusri Elsayed	1.1k 1.0×	414 0.7×	1.1k 1.7×	422 1.0×	606 1.6×	51	2.4k
Ali Amirkhosravi	720 0.7×	898 1.4×	685 1.1×	516 1.2×	253 0.7×	62	2.5k
Michael Loughnan	602 0.6×	937 1.5×	1.2k 1.9×	308 0.7×	251 0.6×	24	2.7k
Stefan Kasper	885 0.8×	395 0.6×	636 1.0×	448 1.1×	397 1.0×	122	2.0k
Akos Czibere	1.2k 1.1×	804 1.3×	1.0k 1.6×	326 0.8×	545 1.4×	112	2.6k
Clay Smith	541 0.5×	1.1k 1.7×	611 1.0×	625 1.5×	162 0.4×	51	2.2k
Tobias Dechow	793 0.7×	275 0.4×	692 1.1×	274 0.6×	475 1.2×	73	2.0k
Joseph Michaeli	694 0.6×	722 1.1×	912 1.4×	118 0.3×	305 0.8×	55	2.0k
Wael A. Harb	1.4k 1.3×	265 0.4×	923 1.5×	259 0.6×	759 2.0×	118	2.5k
Alejandro Martı́n	1.4k 1.3×	909 1.4×	845 1.3×	465 1.1×	249 0.6×	128	2.8k

Countries citing papers authored by Dirk Behringer

Since Specialization

Citations

This map shows the geographic impact of Dirk Behringer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Behringer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Behringer more than expected).

Fields of papers citing papers by Dirk Behringer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Behringer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Behringer. The network helps show where Dirk Behringer may publish in the future.

Co-authorship network of co-authors of Dirk Behringer

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Behringer. A scholar is included among the top collaborators of Dirk Behringer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Behringer. Dirk Behringer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kuon, Jonas, Stefan Wilop, Dirk Behringer, et al.. (2023). 1448P First-line nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC): Results from an interim analysis of the non-interventional FINN study. Annals of Oncology. 34. S823–S824.

Knödler, Maren, Volker Kunzmann, Jörg Trojan, et al.. (2018). Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. British Journal of Cancer. 119(3). 296–302. 66 indexed citations

Schultheis, Beate, Dirk Reuter, M. Ebert, et al.. (2017). Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Annals of Oncology. 28(10). 2429–2435. 97 indexed citations

Schuette, Wolfgang, Dirk Behringer, Jan Stoehlmacher, et al.. (2015). CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non–Small-Cell Lung Cancer With Particular Regard to the KRAS Status. Clinical Lung Cancer. 16(6). 447–456. 10 indexed citations

Sand, Michael, et al.. (2009). Gallbladder metastasis from renal cell carcinoma mimicking acute cholecystitis. European journal of medical research. 14(2). 90–90. 20 indexed citations

Mattern, Dominik, et al.. (2007). Reticulated platelet counts correlate with treatment response in patients with idiopathic thrombocytopenic purpura and help identify the complex causes of thrombocytopenia in patients after allogeneic hematopoietic stem cell transplantation. Cytometry Part B Clinical Cytometry. 72B(4). 241–248. 14 indexed citations

Sissung, Tristan M., K. Mross, Seth M. Steinberg, et al.. (2006). Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. European Journal of Cancer. 42(17). 2893–2896. 136 indexed citations

Spyridonidis, Alexandros, Ralph Wäsch, Miguel Waterhouse, et al.. (2005). Reduced Intensity Conditioning Compared to Standard Conditioning Preserves the In Vitro Growth Capacity of Bone Marrow Stroma, Which Remains of Host Origin. Stem Cells and Development. 14(2). 213–222. 14 indexed citations

Zeiser, Robert, et al.. (2004). Clinical follow‐up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis – a single centre experience. British Journal of Haematology. 124(6). 762–768. 37 indexed citations

10.

Spyridonidis, Alexandros, et al.. (2004). Epithelial Tissue Chimerism after Human Hematopoietic Cell Transplantation Is a Real Phenomenon. American Journal Of Pathology. 164(4). 1147–1155. 55 indexed citations

11.

Batsford, Stephen, Emile Schiltz, Mathias Oelke, et al.. (2003). Identification of beta-subunit of bacterial RNA-polymerase--a non-species-specific bacterial protein--as target of antibodies in primary biliary cirrhosis.. Digestive Diseases and Sciences. 48(3). 561–569. 10 indexed citations

12.

Kunzmann, Regina, et al.. (2003). Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study. Annals of Hematology. 82(7). 381–389. 37 indexed citations

13.

Engelhardt, Monika, et al.. (2001). Hematopoietic recovery of ex vivo perfusion culture expanded bone marrow and unexpanded peripheral blood progenitors after myeloablative chemotherapy. Bone Marrow Transplantation. 27(3). 249–259. 23 indexed citations

14.

Oelke, Mathias, et al.. (2000). Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.. PubMed. 6(5). 1997–2005. 73 indexed citations

15.

Finke, Jürgen, Hartmut Bertz, Claudia Schmoor, et al.. (2000). Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. British Journal of Haematology. 111(1). 303–313. 63 indexed citations

16.

Behringer, Dirk, et al.. (1999). Quantitative lymphocyte subset reconstitution after allogeneic hematopoietic transplantation from matched related donors with CD34+ selected PBPC grafts, unselected PBPC grafts or BM grafts. Bone Marrow Transplantation. 24(3). 295–302. 39 indexed citations

17.

Behringer, Dirk, et al.. (1991). Outcome of patients with refractory ventricular tachyarrhythmias declining automatic implantable cardioverter-defibrillator. Journal of the American College of Cardiology. 17(2). A351–A351. 1 indexed citations

18.

Behringer, Dirk, et al.. (1991). Antibodies against neuroactive amino acids and neuropeptides. I. A new two-step procedure for their conjugation to carrier proteins and the production of an anti-Met-enkephalin antibody reactive with glutaraldehyde-fixed tissues.. Journal of Histochemistry & Cytochemistry. 39(6). 749–760. 17 indexed citations

19.

Behringer, Dirk, et al.. (1991). Antibodies against neuroactive amino acids and neuropeptides. II. Simultaneous immunoenzymatic double staining with labeled primary antibodies of the same species and a combination of the ABC method and the hapten-anti-hapten bridge (HAB) technique.. Journal of Histochemistry & Cytochemistry. 39(6). 761–770. 11 indexed citations

20.

Craswell, P. W., et al.. (1987). Patterns of lead excretion in patients with gout and chronic renal failure — A comparative German and Australian study. The Science of The Total Environment. 66. 17–28. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact